Barclays PLC Lowers Stake in Enovis Corporation $ENOV

Key Points

• Barclays cut its stake in Enovis by 35.2% in Q3, selling 381,242 shares and holding 701,195 shares (1.23% of the company) valued at about $21.27 million.
• Enovis beat Q results with $0.95 EPS vs $0.81 expected and set FY2026 guidance of 3.520–3.730 EPS; the stock is up ~4.1% with a market cap of $1.42 billion and a consensus rating of "Moderate Buy" (average target $47.43).
• Insiders have been net buyers recently (Oliver Engert bought 1,000 shares; insiders own 2.70%), while most analysts remain positive (one Strong Buy, seven Buy, one Sell).

Barclays PLC decreased its position in Enovis Corporation (NYSE:ENOV - Free Report) by 35.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 701,195 shares of the company's stock after selling 381,242 shares during the quarter. Barclays PLC owned 1.23% of Enovis worth $21,274,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Enovis by 2.0% in the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company's stock valued at $197,945,000 after acquiring an additional 125,460 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Enovis by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock valued at $90,156,000 after acquiring an additional 51,201 shares during the period. Hood River Capital Management LLC raised its position in Enovis by 20.3% in the 2nd quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company's stock valued at $54,426,000 after purchasing an additional 292,950 shares during the last quarter. River Road Asset Management LLC raised its position in Enovis by 3.5% in the 2nd quarter. River Road Asset Management LLC now owns 1,439,923 shares of the company's stock valued at $45,156,000 after purchasing an additional 48,036 shares during the last quarter. Finally, Boston Partners boosted its stake in Enovis by 42.4% during the 2nd quarter. Boston Partners now owns 1,382,724 shares of the company's stock worth $43,352,000 after purchasing an additional 411,744 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Up 4.1%

Shares of NYSE ENOV opened at $24.87 on Thursday. The firm's 50-day moving average is $23.94 and its two-hundred day moving average is $27.91. The company has a market capitalization of $1.42 billion, a PE ratio of -1.20 and a beta of 1.46. Enovis Corporation has a 12-month low of $21.00 and a 12-month high of $40.69. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The business had revenue of $575.76 million during the quarter, compared to analysts' expectations of $584.30 million. During the same period last year, the company posted $0.98 EPS. The company's revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on ENOV. Canaccord Genuity Group dropped their price objective on shares of Enovis from $58.00 to $50.00 and set a "buy" rating on the stock in a research note on Wednesday, December 17th. UBS Group reiterated a "buy" rating and set a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. BTIG Research raised their price target on Enovis from $41.00 to $43.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Evercore reiterated an "outperform" rating on shares of Enovis in a report on Monday, January 12th. Finally, Zacks Research raised shares of Enovis from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Enovis has a consensus rating of "Moderate Buy" and an average price target of $47.43.

Insiders Place Their Bets

In other news, insider Oliver Engert bought 1,000 shares of the business's stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider owned 43,640 shares of the company's stock, valued at $1,112,820. This trade represents a 2.35% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have bought 4,000 shares of company stock valued at $98,243. Insiders own 2.70% of the company's stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.